UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On November 10, 2022, Ultragenyx Pharmaceutical Inc. (the “Company”) announced that Mardi Dier had informed the Company of her decision to voluntarily resign from her position as the Company’s Executive Vice President and Chief Financial Officer, effective as of November 15, 2022, to pursue another opportunity. The Company has commenced a formal search for a new Executive Vice President and Chief Financial Officer.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 10, 2022 | Ultragenyx Pharmaceutical Inc. | |||||
| By: | /s/ Emil D. Kakkis, M.D., Ph.D. | |||||
| Emil D. Kakkis, M.D., Ph.D. | ||||||
| President and Chief Executive Officer | ||||||
Document and Entity Information |
Nov. 10, 2022 |
|---|---|
| Cover [Abstract] | |
| Amendment Flag | false |
| Entity Central Index Key | 0001515673 |
| Document Type | 8-K |
| Document Period End Date | Nov. 10, 2022 |
| Entity Registrant Name | ULTRAGENYX PHARMACEUTICAL INC. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-36276 |
| Entity Tax Identification Number | 27-2546083 |
| Entity Address, Address Line One | 60 Leveroni Court |
| Entity Address, City or Town | Novato |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 94949 |
| City Area Code | (415) |
| Local Phone Number | 483-8800 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, $0.001 par value |
| Trading Symbol | RARE |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G